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MOLECULAR DIAGNOSTICS AND THE
ROAD TRAVELED
For the last three decades, finding
genes responsible for inherited diseases
relied mostly on genetic linkage studies
and candidate gene screening. Often
slow, labor-intensive, and unfulfilled,
this approach of the late 20th Century
nevertheless led to the identification of
a number of inherited disease genes.
These data, combined with the deve-
lopment of PCR-based methods for
amplification of genomic DNA and
mutation detection, led to more accu-
rate diagnoses, better genetic coun-
seling, and translational benefits for
patients such as new prenatal diag-
nostic tests, as well as a platform to
develop new disease mechanism–
based models and therapies (see Uitto,
2012). The most prevalent genetic
variants causative for specific common
disorders (e.g., p.Phe508del in the
CFTR gene in cystic fibrosis, and
p.Gly6Val in the HBB gene in sickle
cell anemia) were deemed clinically
and economically suitable to format
into focused diagnostic products. In
contrast, for the genodermatoses, the
relative rarity of these skin diseases and
the lack of recurrent mutations meant
that molecular progress has not led to
similar developments. Notably, DNA
diagnostics for inherited skin diseases
have remained mostly confined to a few
academic and hospital laboratories.
Recently, however, gene hunting and
mutation detection has moved into an
era in which next-generation sequen-
cing technologies recast not only the
scientific discovery process but also
the logic of detecting such inherited
markers in the clinic.
EPIDERMOLYSIS BULLOSA AND THE
DIAGNOSTIC JOURNEY
This journey of molecular discovery in
inherited skin diseases is exemplified
by the disease epidermolysis bullosa
(EB) (see Bruckner-Tuderman and Has,
2012). Transmission electron micro-
scopy in the 1960s was able to estab-
lish three distinct levels of blister
formation, thus providing diagnostic
categories of EB into simplex, junc-
tional, and dystrophic (Pearson, 1962).
In the 1980s, the introduction of anti-
gen mapping (Hintner et al., 1981) and
immunofluorescence microscopy using
new anti-basement membrane zone
antibodies (Fine et al., 1984) was able
to speed up diagnostic subtyping—most
recessive types of EB could be rapidly
diagnosed within 2–3 days based on the
skin biopsy immunoreactivity (or lack
thereof) to specific probes. In the
1990s, the genes for the major forms
of EB were cloned and a plethora of
pathogenic mutations emerged (for
review, see Varki et al., 2006, 2007).
Genetic characterization proved parti-
cularly useful in making accurate diag-
noses in mild cases of EB in which
the skin biopsy findings were too subtle
to discriminate between subtypes.
Currently, mutations in 14 different
genes have been implicated in the
pathogenesis of the various types of EB.
MUTATION DETECTION AND THE
MOLECULAR ROUTE MAP
But there have been limitations to
current molecular diagnostics: deli-
neating a single DNA mutation within
the gene encoding a single skin protein
does not give you all the answers,
either biological or clinical. Disparity
in genotype–phenotype correlations,
mosaic patterns of disease, inter- and
intra-familial variability, and differing
prognoses and disease behaviors are all
familiar to dermatologists and clinical
geneticists. Since the discovery of the
structure of the DNA double helix in
1953 (Watson and Crick, 1953), there
have been several notable milestones
in the development of DNA sequen-
cing. From Sanger’s chain termination
sequencing introduced in the late
1970s through its advancement by
way of fluorescent labeling and capil-
lary electrophoresis in the 1990s, to the
recent introduction of massive parallel
sequencing, advances in DNA sequen-
cing have accelerated and clinical
translation has beckoned (Pettersson
et al., 2009). Next-generation sequen-
cing methodologies have reduced
the cost of characterization of the
6 billion nucleotides composing a
diploid genome to less than $2,000
(April 2012 costs). Affordability of
high-resolution epigenetic assessment
has kept pace, with interrogation of
B80% of genomic CpGs for less than
$2,000 and whole-genome localization
of histone marks for as little as B$500
(Cheng and Cho, 2012). The plummet-
ing cost of diagnostics, however, poses
paradoxical difficulties—whereas clini-
cians once grappled with potential
diagnoses missed by limited tests, the
future is likely to overwhelm with large
numbers of genetic variants of uncer-
tain significance.
CLINICAL DIAGNOSTICS AND FORKS
IN THE ROAD
This generally inverse relationship bet-
ween informativeness and actionability
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of a clinical test is a crucial prism to
examine the evolution of genetic test-
ing. The simple, consistent conforma-
tional changes induced by sickle cell
anemia variants have enabled cheap
chromatography–based tests, often less
than $50 in cost, to persist as first-
line screening to the current day
(Nalbandian et al., 1975). Similarly,
testing for hexosaminidase A levels
adopted broadly in the 1960s remains
the most common means of testing for
Tay-Sachs disease. However, the cost
of DNA sequencing in that interval
has dropped toB$150–200 for specific
genetic variants. Today, a similar sort of
sum (perhaps B$500) can purchase
sequencing of the entire protein-coding
region of a genome (about 60–70
million nucleotides). Consequently,
the greatest competition for the tradi-
tional Tay-Sachs test may not be a
Tay-Sachs test, but one screening
dozens to hundreds of metabolic genes
carrying mutations in Ashkenazi Jews
(Srinivasan et al., 2010). The burden of
interpreting some of these extremely
rare variants, with unpredictable clini-
cal penetrance, falls increasingly on the
treating subspecialist.
CREATING A DIAGNOSTIC PATH FOR
GENODERMATOSES
With regard to genodermatoses, how-
ever, there are some specific challenges.
In contrast to classic quantitative traits,
such as metabolic disease or blood
pressure, the more specific and discrete
morphological phenotypes typifying
many dermatoses (e.g., epidermal blis-
tering diseases) have revealed surpri-
singly diverse genes converging on a
common phenotype. Today, we under-
stand that a truly comprehensive genetic
diagnostic for an unclassified ichthyosis
must survey dozens of genes regulating
cholesterol metabolism, immunoglobu-
lin regulation, cytoarchitectural compo-
nents, and determinants of terminal
keratinocyte differentiation, each candi-
date defect linked to a distinct spectrum
of systemic manifestations (Oji et al.,
2010). The morpho-spatial nature of
genodermatoses also adds the conun-
drum of mosaic disease (Cho, 2010).
The visible lesions defining the skin
disease may represent clonal muta-
tions (as in epidermal nevi), and any
genetic testing must therefore sample
affected tissue directly in these dis-
orders. In the absence of available
commercial therapeutics for many of
these conditions, let alone genetic
counselors familiar with the clinical
implications of rare genodermatoses,
the impetus to advance such testing
has often come from patients rather
than clinicians or pharmaceutical
companies.
EXOME SEQUENCING AND THE WAY AHEAD
Exome sequencing represents a signifi-
cant milestone in the development of
next-generation diagnostics for inher-
ited skin diseases (Ng et al., 2009).
Already, this approach has proved
insightful in revealing the molecular
pathology of more than a dozen pre-
viously uncharacterized genoderma-
toses (for update see Cheng and Cho,
2012). The 2012 cost of exome sequen-
cing in a case of suspected EB is similar
to that required for the skin biopsy
analysis (basement membrane immu-
nohistochemistry and transmission
electron microscopy) but a key issue
in terms of the clinical interface is test
turnaround time. For exome sequen-
cing, the time needed to undertake data
analysis and filtering represents the
major hurdle to maximizing clinical
utility—sometimes deciphering the
bioinformatics over a few weeks is
suboptimal, at least to clinicians (and
patients). Nevertheless, within the next
year or so, sequencing a genome in a
day will be both feasible and afford-
able. Combined with practical bio-
informatic approaches to enable rapid
targeted interrogation of a specific
disease gene (or panel of genes), next-
generation sequencing is perhaps des-
tined to change the way that inherited
skin diseases such as EB are diagnosed.
With that goal, another milestone in the
diagnosis of genodermatoses will then
have been reached.
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